文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

二尖瓣环钙化的诊断与管理:要点与陷阱

Pearls and pitfalls in the diagnosis and management of mitral annular calcification.
PubMed 文献 · Heart · 2026-01-20

本文综述了二尖瓣环钙化(MAC)的病理生理、诊断挑战与管理策略。MAC在发达国家已成为二尖瓣狭窄的首要病因,其进展受年龄、慢性肾病和代谢紊乱加速。传统超声指标常不可靠,需结合三维超声和心脏CT等多模态影像评估;管理应优先药物治疗,干预仅限特定患者并在专科中心进行。

要点

  • MAC在发达国家已超越风湿病成为二尖瓣狭窄的首位病因。
  • 诊断MAC相关瓣膜功能障碍需多模态影像,传统超声指标常不可靠。
  • 管理优先药物治疗,手术/经导管干预风险高,仅限专科中心选择患者。

核心结论

  • MAC是进展性退行性过程,可导致二尖瓣功能障碍、心律失常、系统性栓塞和心血管风险升高。
  • 管理应优先药物治疗以控制症状和合并的HFpEF,干预仅用于选择患者并在专科中心进行。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 在发达国家,MAC已超越风湿病成为二尖瓣狭窄的首要病因。
  • MAC进展受年龄、慢性肾病和代谢紊乱加速。
  • 症状常反映合并瓣膜病(如主动脉瓣狭窄)和心肌病(如HFpEF表型),需仔细血流动力学评估以避免无效干预。
  • 手术和经导管方法风险高,应仅在专科中心开展。

关键数值与推荐

  • 传统超声心动图测量常不可靠,多模态影像(包括三维超声和心脏CT)对评估解剖、功能和手术可行性至关重要。

临床怎么用

  • 对MAC患者应使用多模态影像评估瓣膜功能障碍和手术可行性。
  • 优先药物治疗控制症状和合并HFpEF,谨慎选择干预患者并转诊至专科中心。

局限性

  • 本文为综述,未报告原始研究数据或系统评价方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mitral annular calcification (MAC) is a progressive, degenerative process increasingly recognised for its clinical impact. Beyond being an incidental finding, MAC contributes to mitral valve dysfunction, arrhythmias, systemic embolisation and elevated cardiovascular risk. In developed countries, it has now overtaken rheumatic disease as the leading cause of mitral stenosis.The pathophysiology of MAC involves chronic mechanical stress, pro-inflammatory activation and osteogenic differentiation of valvular cells. Progression is accelerated by age, chronic kidney disease and metabolic derangements. Diagnosing MAC-related valve dysfunction is challenging, as traditional echocardiographic measures often prove unreliable. Multimodality imaging-including 3D echocardiography and cardiac CT-is essential for assessing anatomy, function and procedural feasibility. Importantly, symptoms often reflect combined valvular (eg, aortic stenosis) and myocardial disease (eg, heart failure with preserved ejection fraction (HFpEF) phenocopy), necessitating careful haemodynamic evaluation to avoid futile interventions.Management should prioritise medical therapy for symptom control and comorbid HFpEF, reserving interventions for selected patients. Surgical and transcatheter approaches carry high risk and should be undertaken only in specialised centres. Future advances may include tailored devices and therapies targeting calcification pathways.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Dhont S, van den Acker GPH, Churchill TW, et al. Pearls and pitfalls in the diagnosis and management of mitral annular calcification. Heart. 2026. PMID: 41558851. doi:10.1136/heartjnl-2025-325937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。